Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 trial

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 696-705

  Udell, Jacob A ^a   Bhatt, Deepak L ^b   Braunwald, Eugene ^b   Cavender, Matthew A ^b   Mosenzon, Ofri ^c   Steg, Ph Gabriel ^d,e   Davidson, Jaime A ^f   Nicolau, Jose C ^g   Corbalan, Ramon ^h   Hirshberg, Boaz ⁱ   Frederich, Robert ^j   Im, KyungAh ^b   Umez Eronini, Amarachi A ^b   He, Ping ^b   McGuire, Darren K ^f   Leiter, Lawrence A ^k   Raz, Itamar ^c   Scirica, Benjamin M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BICHAT HOSPITAL   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁱ ASTRAZENECA   (United Kingdom)

^j BRISTOL MYERS SQUIBB   (United States)

^k ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; INCIDENCE; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME;

ADAMANTANE; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME;

EID: 84942789301     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1850     Document Type: Article

References (37)

1. Tonelli M, Muntner P, Lloyd A, et al.; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 2012; 380:807-814.
2. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495.
3. Jardine MJ, Hata J, Woodward M, et al.; ADVANCE Collaborative Group. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis 2012;60:770-778.
4. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003:S24-S31.
5. McCullough PA, Li S, Jurkovitz CT, et al.; KEEP Investigators. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 2008;156:277-283.
6. Fox CS, Matsushita K, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individualswith and without diabetes: A meta-analysis. Lancet 2012;380:1662-1673.
7. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 2012;27:2650-2657.
8. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014;37(Suppl.1):S14-S80.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
10. Slinin Y, Ishani A, Rector T, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: A systematic reviewfor a KDOQI Clinical Practice Guideline. Am J Kidney Dis 2012;60:747-769.
11. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012;156: 570-581.
12. Nowicki M, Rychlik I, Haller H, et al. Longterm treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-1239.
13. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117: 574-584.
14. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.
15. Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417-426.
16. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818-825, e6.
17. Scirica BM, Braunwald E, Raz I, et al.; for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1578-1588.
18. Udell JA, Scirica BM, Braunwald E, et al. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardiol 2012;35:722-729.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470.
20. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147.
21. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-265.
22. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8: 551-561.
23. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997;54:201-208.
24. Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care 2009;32(Suppl. 2):S337-S341.
25. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
26. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-1437.
27. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380-c383.
28. Roussel R, Travert F, Pasquet B, et al.; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin useand mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170: 1892-1899.
29. Ekstrom N, Schïoler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: A cohort study from the Swedish National Diabetes Register. BMJ Open 2012;2:e001076.
30. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28:539-543.
31. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 2010;55:835-847.
32. Morikawa A, Ishizeki K, Iwashima Y, et al. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. Clin Exp Nephrol 2011;15:848-853.
33. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289.
34. Erdmann E, Charbonnel B, Wilcox RG, et al.; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773- 2778.
35. Komajda M, McMurray JJV, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824-831.
36. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328.
37. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335.